HPV Isn't Just a Women's Problem: What Men Need to Know

Published: August 2025 | Last updated: May 2026

Your partner just told you she has HPV. Now you are trying to figure out what that means for you, what to test for, and whether you have done something wrong. The short version: HPV is one of the most common viruses humans encounter, most sexually active adults will carry at least one strain at some point, and the next step is rarely panic. It is usually a short list of practical actions: understand what HPV does in male bodies, get the testing that is available to you, ask about vaccination if you are under 45, and have a calm follow-up conversation with your partner.

This article is written for the male reader who has just heard the news. It is sourced from current CDC, American Cancer Society, and NHS guidance and reviewed by a licensed physician for clinical accuracy.

Why HPV usually flies under the radar in men

HPV is a family of more than 200 related viruses. About 40 of them spread through sexual contact. They infect the basal layer of skin and mucous membranes, including the genital, anal, and oropharyngeal (back of the throat) regions. Most infections produce no symptom a person can feel or see. They live in the tissue, replicate, and either get cleared by the immune system over months to years or persist quietly.

In male bodies the surveillance gap is wider than in female bodies. Women receive routine cervical screening (Pap test, with or without an HPV co-test) starting at age 21 or 25 depending on the guideline a clinician follows. That screening catches both visible disease and the microscopic precancerous changes high-risk HPV strains cause. Men have no equivalent. There is no FDA-approved general screening test for asymptomatic HPV in male patients. Pap-style screening of the anal canal exists in specialty clinics for higher-risk groups (more on that below) but is not part of routine adult primary care.

The result is a man may carry HPV for years without ever entering the testing system. Two outcomes happen most often. His immune system clears the strain quietly, or it persists silently and shows up later as visible warts, dysplasia (precancerous tissue change), or in worst cases a cancer of the affected tissue. Neither outcome announces itself before the fact.

This pattern produces asymmetric awareness. A woman whose Pap returns abnormal hears the word HPV from her clinician and starts asking questions. Her male partner, who may have been the source or may have been exposed alongside her, hears about HPV only when she tells him. He has no parallel test to take. He has the public-health guidance instead: most exposures resolve, some do not, and the available tools are vaccination and prompt evaluation of anything unusual.

That surveillance gap is a feature of how HPV behaves in male tissue and a gap in the diagnostic technology available today, not a moral failure or a screening conspiracy. The sections below cover what you can do.

There is no routine HPV test for men, and that is real

This is the part that surprises most male readers. There is no at-home HPV screening swab approved for asymptomatic men in the U.S. There is no urine HPV test in routine clinical use. The standard adult STI panel a clinician orders during a check-up screens for chlamydia, gonorrhea, syphilis, HIV, and (depending on history) hepatitis B and C. HPV is not on the standard male panel.

What is available:

• Visual examination by a clinician of any visible bumps, papules, or skin changes in the genital, anal, or perianal region. Warts are usually identifiable on inspection.
• Biopsy of any suspicious lesion. The tissue can be HPV-typed at the pathology lab to identify the specific strain.
• Anal cytology (an anal Pap) and high-resolution anoscopy at some specialty clinics for men who have sex with men, immunocompromised patients, or those with documented anal HPV history. Not yet a routine offering for the general male population.
• Throat examination by a primary-care clinician or ENT specialist for any persistent symptom such as a non-healing sore, hoarseness lasting weeks, a lump in the neck, or trouble swallowing.

What is not available:

• A routine self-collected HPV screening swab for asymptomatic men.
• A blood test for HPV. The virus does not circulate in blood in a way standard antibody or antigen assays can pick up reliably.
• A general home test for asymptomatic male HPV from any U.S. retailer.

The diagnostic gap is real. The reason is that the available technology was developed around screening the cervix, where the sampling access point is well defined and the cancer endpoint (cervical cancer) is well characterized.

How HPV transmits

HPV spreads through direct skin-to-skin contact with infected tissue. Penetrative sex is not required. Genital-to-genital contact, oral-to-genital contact, and digital-to-genital contact can all transmit the virus when one surface has active viral replication and the other has a microscopic break in the skin barrier. Those breaks are essentially always present from normal friction and grooming.

What this means practically:

• Condoms reduce HPV transmission but do not eliminate it. The virus infects skin a condom does not cover. CDC guidance on genital HPV describes condom use as protective but partial.
• Asymptomatic carriers transmit the virus. Visible warts are not required for transmission. Most transmission happens between people who do not know they are carrying it.
• The per-encounter risk is hard to quantify, but cumulative exposure over a relationship is high. The CDC has estimated that most sexually active adults will be exposed to at least one HPV strain in their lifetime if they were not vaccinated as adolescents.
• Non-sexual transmission and vertical transmission (parent to infant during birth) have been documented but are not the primary route in adults.

For a man whose partner has just disclosed an HPV diagnosis, the question of who carried it first is usually impossible to answer. HPV can stay dormant for months or years before detection. Partner A may have carried a strain since a relationship five years earlier and never known. Partner B may have just acquired it. The disclosure event tells you HPV is in the picture. It does not tell you when, where, or from whom.

Treating the disclosure as a fact rather than an accusation is the only useful framing. Public-health agencies are explicit on this point: HPV is so common and so often dormant that partner-to-partner blame is almost always unsupported by the biology.

HPV-related cancers in men: what is real, what is rare

The most consequential HPV question for men is the cancer risk. About a dozen HPV strains are classified as high-risk for cancer. Of these, HPV 16 is responsible for most HPV-associated cancers in men, with HPV 18 contributing a smaller share. Three cancers carry the strongest HPV link in men.

Oropharyngeal cancer. The U.S. has seen a marked rise in HPV-positive cancers of the tonsils, base of tongue, and soft palate over the past two decades. HPV now accounts for the majority of oropharyngeal cancers diagnosed in the U.S., with men affected at a substantially higher rate than women, according to CDC surveillance data on HPV-associated cancers. The natural history is long: exposure in young adulthood, slow persistence in oropharyngeal tissue, presentation as a painless neck lump, persistent sore throat, or hoarseness in middle age. There is no routine screening for oropharyngeal HPV in male patients today.

Anal cancer. Anal HPV infection is the proximate cause of nearly all anal cancers. Absolute incidence in the general male population is low (roughly 800 new cases per year among U.S. men according to CDC surveillance), but the risk is meaningfully higher in men who have sex with men, and substantially higher again in men who are immunocompromised (including HIV-positive men). Anal Pap and high-resolution anoscopy programs at specialty clinics serve these higher-risk groups.

Penile cancer. Penile cancer is uncommon in the U.S. (about 1 case per 100,000 men per year). HPV is implicated in roughly half of penile cancers. Risk factors include chronic inflammation, phimosis, smoking, and persistent high-risk HPV infection.

HPV-related cancers are a minority of all male cancers. But the cancers HPV does cause are largely silent during the long pre-clinical phase, and the only preventive tool with strong evidence behind it is the HPV vaccine. Screening for these cancers in the general male population is not part of routine adult care, so prevention upstream (vaccine, condom use, not smoking, prompt evaluation of any persistent sore, lump, or skin change) is the available approach.

HPV is so common that nearly all sexually active people will get HPV at some time in their lives if they don't get vaccinated. About 13 million Americans, including teens, become infected with HPV each year.

The HPV vaccine for men, by age

The HPV vaccine (Gardasil 9 in the U.S.) protects against nine strains, including the seven most strongly linked to HPV-associated cancers and the two strains responsible for about 90 percent of genital warts. The Advisory Committee on Immunization Practices (ACIP) recommends it on the following pattern, summarized from the CDC HPV vaccination program page:

• Routine vaccination for everyone through age 26. Two doses if the series starts before age 15, three doses if it starts at age 15 or later.
• Shared clinical decision-making for adults aged 27 through 45. The vaccine is FDA-approved for this age range. You and your clinician decide together whether it makes sense based on your sexual history, current relationship structure, and likely future exposure.

The vaccine is not retroactive. It does not clear strains you already carry. Its value for adults is protection against the strains in the vaccine you have not yet been exposed to. For a man with multiple partners over time, a man in a new relationship, or a man whose relationship structure may change in the future, that protection is meaningful.

The series is three injections over six months for adults starting the schedule at 15 or older. Most insurance plans cover it for the recommended age groups. Out-of-pocket cost varies; current adult pricing in the U.S. is in the range of about $200 to $300 per dose without coverage.

The recommendation drops off after 45. There is no upper-age FDA cutoff, but coverage and population-level benefit become smaller above that age, and the decision is more individual.

If you have not been vaccinated and you are under 45, this is the single most-supported HPV action available to you. Asking your primary-care provider or a sexual-health clinic about scheduling the first dose takes one short visit.

What to do this week, in order

Here is the practical list for a man whose partner has just disclosed an HPV diagnosis, in rough priority order.

1. Take a slow breath. The disclosure is information, not an emergency. Most HPV exposures resolve without progression to disease.
2. Have the follow-up conversation with your partner about what was found. Was it a low-risk strain (typically HPV 6 or 11, the wart-causing types) or a high-risk strain (HPV 16, HPV 18, or another oncogenic type)? A low-risk finding changes the conversation. A high-risk finding changes the long-term monitoring plan for her, but does not change your immediate plan much.
3. Inspect any visible changes. A persistent soft bump, papule, rough patch, or color change in the genital, anal, or perianal area is worth a clinic visit. Most of what a man notices is not a wart, but a brief in-person exam settles it.
4. Schedule a broader STI check. An HPV disclosure is a reasonable trigger to confirm your status on the infections that have validated at-home tests or routine clinic panels: HIV, syphilis, chlamydia, gonorrhea, hepatitis B and C. Most clinics offer combined panels.
5. Ask about HPV vaccination if you have not had it. Through age 26 is the routine recommendation. Through age 45 is shared decision-making. The vaccine does not change what you already carry, but it protects against future exposures.
6. Plan condom use going forward. Condoms reduce HPV transmission, do not eliminate it, and reduce a number of other STIs more reliably. This is part of the broader sexual-health conversation, not a separate one.
7. Do not assign blame. The disclosure event reveals presence, not provenance. HPV biology rules out useful blame assignment in nearly every case.

This list is sequential rather than simultaneous. You can take a breath, talk with your partner, and book a clinic visit this week. The vaccine conversation can happen at the same visit. The at-home STI panel can run in the background while you arrange the in-person appointment.

8-in-1 At-Home STI Panel (men and women)

Complete 8-in-1 STD At-Home Rapid Test Kit

$472.00

An HPV disclosure is a reasonable prompt to confirm your status on the STIs that do have validated at-home tests. This rapid lateral-flow panel covers HIV, Syphilis, Hepatitis B, Hepatitis C, Chlamydia, Gonorrhea, Herpes (HSV-2), and Trichomoniasis. Fingerstick blood draw plus self-collected swab where applicable. Results in about 15 minutes per test. Note 1: this panel does not test for HPV; no at-home male HPV test exists today. Visible findings need a clinic visit. Note 2: the trichomoniasis swab component is validated for vaginal self-swab only. Male readers who need trichomoniasis testing should see a clinic for that specific test.

See the 8-in-1 panel

1. U.S. Centers for Disease Control and Prevention. About genital HPV infection: transmission, symptoms, prevention, and condom-effectiveness guidance.
2. U.S. Centers for Disease Control and Prevention. HPV vaccination program: ACIP recommendations covering routine vaccination through age 26 and shared clinical decision-making through age 45.
3. U.S. Centers for Disease Control and Prevention. Cancers associated with HPV in the United States: surveillance data on oropharyngeal, anal, and penile cancers in men.
4. American Cancer Society. HPV and cancer: background on the strains linked to HPV-associated cancers in men.
5. U.S. National Cancer Institute. HPV and cancer: virus types, persistent infection, and cancer risk.
6. NHS. Human papillomavirus (HPV): overview, symptoms, vaccination program.

Sam Harper

Sam covers at-home sexual-health testing, public-health guidance, and clinical-testing basics for general audiences. Has been writing about consumer health since 2019, with a focus on translating CDC and WHO guidance into plain-English action items. Not a clinician; articles are summaries, not advice.